US YUTIQ Market Size, Forecast, and Market Insight - 2032

“YUTIQ Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about YUTIQ for autoimmune uveitis in the US. A detailed picture of the YUTIQ for autoimmune uveitis in the US for the study period 2019 -2032 is provided in this report along with a detailed description of the YUTIQ for autoimmune uveitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the YUTIQ market forecast analysis for autoimmune uveitis in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.

Drug Summary

YUTIQ is a sterile nonbioerodible intravitreal implant with 0.18 mg FA (fluocinolone acetonide). It releases the drug at an initial rate of 0.25 μg/day in a 36-month sustained-release drug delivery system. YUTIQ contains a corticosteroid and is indicated for treating chronic noninfectious uveitis affecting the posterior segment of the eye. It is preloaded into a single-dose applicator to facilitate the injection of the implant directly into the vitreous. It was approved by the FDA in October 2018 and commercially launched in the US in February 2019.

YUTIQ was designed to improve the performance of RETISERT to deliver a lower dose of corticosteroid to the retina with fewer adverse events; it increased intraocular pressure (IOP) and cataract, reducing the patient inconvenience and side effects associated with application methods. Moreover, the long-lasting effect decreases the dosing frequency. EyePoint is also developing a next-generation, shorter-duration treatment for chronic noninfectious uveitis affecting the posterior segment of the eye, based on the Durasert technology. This insert is designed to offer a shorter delivery period, thus providing physicians with flexibility for multiple dosing intervals.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the YUTIQ description, mechanism of action, dosage and administration, research and development activities in autoimmune uveitis.
• Elaborated details on YUTIQ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the YUTIQ research and development activities in autoimmune uveitis across the US.
• The report also covers the patents information with expiry timeline around YUTIQ.
• The report contains forecasted sales of YUTIQ for autoimmune uveitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for autoimmune uveitis.
• The report also features the SWOT analysis with analyst views for YUTIQ in autoimmune uveitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

YUTIQ Analytical Perspective

In-depth YUTIQ Market Assessment

This report provides a detailed market assessment of YUTIQ for autoimmune uveitis in the US. This segment of the report provides forecasted sales data from 2024 to 2032.

YUTIQ Clinical Assessment

The report provides the clinical trials information of YUTIQ for autoimmune uveitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for autoimmune uveitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence YUTIQ dominance.
• Other emerging products for autoimmune uveitis are expected to give tough market competition to YUTIQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of YUTIQ in autoimmune uveitis.
• Our in-depth analysis of the forecasted sales data of YUTIQ from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the YUTIQ in autoimmune uveitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of YUTIQ?
• What is the clinical trial status of the study related to YUTIQ in autoimmune uveitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the YUTIQ development?
• What are the key designations that have been granted to YUTIQ for autoimmune uveitis?
• What is the forecasted market scenario of YUTIQ for autoimmune uveitis?
• What are the forecasted sales of YUTIQ in the US?
• What are the other emerging products available and how are these giving competition to YUTIQ for autoimmune uveitis?
• Which are the late-stage emerging therapies under development for the treatment of autoimmune uveitis?

This product will be delivered within 2 business days.